Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margitta Retz

Showing results (1-10 of 99) with videos related to

Pageof 10
Sort By:
Critical Reviews in Oncology/Hematology|August 6, 2003
Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trialJan Lehmann, Margitta Retz, Michael Stöckle
Aktuelle Urologie|June 8, 2017
[The role of immunooncology in the treatment of urothelial cancer]Margitta Retz, Robert Tauber, Thomas Horn
World Journal of Urology|August 28, 2002
Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapyJan Lehmann, Margitta Retz, Michael Stöckle
Aktuelle Urologie|May 21, 2021
Heidrun Rexer, Hubert Kübler, Margitta Retz
Urologie (Heidelberg, Germany)|September 5, 2024
[Paradigm shift in systemic therapy for metastatic urothelial carcinoma-antibody-drug conjugates (ADCs) and fibroblast growth factor receptor (FGFR) inhibitors]Jozefina Casuscelli, Gunhild von Amsberg, Margitta Retz
MMW Fortschritte Der Medizin|November 25, 2010
[Managing side effects of androgene deprivation in prostate cancer]Mark Thalgott, Jürgen E Gschwend, Margitta Retz
Urologic Oncology|March 6, 2016
Quality of life in patients with cisplatin-resistant urothelial cancer: Typical ailments and effect of paclitaxel-based salvage therapyGuenter Niegisch, Margitta Retz, Roswitha Siener, et al.
Aktuelle Urologie|September 18, 2013
[Bladder cancer - neoadjuvant therapy with cisplatin and gemcitabine]Sebastian C Schmid, Jürgen E Gschwend, Margitta Retz
Translational Andrology and Urology|January 28, 2016
Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patientsMatthias M Heck, Jürgen E Gschwend, Margitta Retz
Urologie (Heidelberg, Germany)|January 8, 2025
[Enfortumab vedotin and pembrolizumab : Management of side effects during first line combined treatment for advanced or metastatic urothelial carcinoma]Margitta Retz, Marc-Oliver Grimm, Katharina Leucht, et al.
Pageof 10

Showing results (1-10 of 99) with videos related to

Sort By:
Pageof 10
Critical Reviews in Oncology/Hematology|August 6, 2003
Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trialJan Lehmann, Margitta Retz, Michael Stöckle
Aktuelle Urologie|June 8, 2017
[The role of immunooncology in the treatment of urothelial cancer]Margitta Retz, Robert Tauber, Thomas Horn
World Journal of Urology|August 28, 2002
Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapyJan Lehmann, Margitta Retz, Michael Stöckle
Aktuelle Urologie|May 21, 2021
Heidrun Rexer, Hubert Kübler, Margitta Retz
Urologie (Heidelberg, Germany)|September 5, 2024
[Paradigm shift in systemic therapy for metastatic urothelial carcinoma-antibody-drug conjugates (ADCs) and fibroblast growth factor receptor (FGFR) inhibitors]Jozefina Casuscelli, Gunhild von Amsberg, Margitta Retz
MMW Fortschritte Der Medizin|November 25, 2010
[Managing side effects of androgene deprivation in prostate cancer]Mark Thalgott, Jürgen E Gschwend, Margitta Retz
Urologic Oncology|March 6, 2016
Quality of life in patients with cisplatin-resistant urothelial cancer: Typical ailments and effect of paclitaxel-based salvage therapyGuenter Niegisch, Margitta Retz, Roswitha Siener, et al.
Aktuelle Urologie|September 18, 2013
[Bladder cancer - neoadjuvant therapy with cisplatin and gemcitabine]Sebastian C Schmid, Jürgen E Gschwend, Margitta Retz
Translational Andrology and Urology|January 28, 2016
Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patientsMatthias M Heck, Jürgen E Gschwend, Margitta Retz
Urologie (Heidelberg, Germany)|January 8, 2025
[Enfortumab vedotin and pembrolizumab : Management of side effects during first line combined treatment for advanced or metastatic urothelial carcinoma]Margitta Retz, Marc-Oliver Grimm, Katharina Leucht, et al.
Pageof 10